The First Hospital Affiliated to Xiamen University
Xiamen, China
NCT Number: NCT01418027
The prevalence of NAFLD is 50-70% in obese people. A decrease of calorie intake and increase of physical activity are recommended as an effective approach for the prevention and treatment of NAFLD. However, the exercise model for NAFLD intervention is understudied. In the present study we aim to compare the effect of intensive and conventional exercise interventions on NAFLD.
Looking for future studies?
Notify Me40 year–65 year
All sexes
Interventional
Phase 3
Xiamen, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
Time frame: 12 months
Time frame: 12 months
Time frame: 12 months
Time frame: 12 months
Time frame: 12 montshs
Time frame: 12 months
Time frame: 12 months
Time frame: 12 months
Shanghai Jiao Tong University School of Medicine
Other
Combined Intensive and Conventional Exercise Intervention of Nonalcoholic Fatty Liver Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04682600
Digestive System Diseases, Fatty Liver
Boston, Massachusetts, United States
View Trial DetailsNCT04639414
Diabetes Mellitus, Diabetes Mellitus, Type 2
Graz, Austria
View Trial DetailsNCT06627114
Body Weight, Digestive System Diseases
Erbil, Kurdistan Region, Iraq
View Trial DetailsNCT07268937
Digestive System Diseases, Fatty Liver
Pavia, Italy
View Trial Details